J.P. Morgan analyst Rachel Vatnsdal has maintained their neutral stance on XRAY stock, giving a Hold rating yesterday.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Rachel Vatnsdal’s rating is based on several factors surrounding DENTSPLY SIRONA’s recent financial performance and strategic changes. The company preannounced its second-quarter revenue, which slightly exceeded market expectations, indicating stable financial health. However, the anticipated organic revenue decline and the earnings per share forecast that aligns closely with market predictions suggest limited growth potential in the near term.
Additionally, the transition in leadership with Daniel Scavilla taking over as CEO introduces an element of uncertainty, despite his extensive experience in the medtech and pharma industries. While the company’s reaffirmed guidance for 2025 shows consistency, the combination of these factors leads to a cautious outlook, justifying the Hold rating as investors may want to wait for more clarity on the company’s strategic direction and performance under new leadership.
In another report released yesterday, Bank of America Securities also maintained a Hold rating on the stock with a $17.00 price target.